ÂÜÀòÂÒÂ×

Paul Clancy has served on Xilio’s board of directors since July 2020 and brings more than 35 years of experience in financial management and strategic business planning. Mr. Clancy most recently served as executive vice president, senior advisor of Alexion Pharmaceuticals, Inc., and earlier served as chief financial officer of Alexion. Prior to Alexion, Mr. Clancy served as the executive vice president and chief financial officer at Biogen Inc. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., serving in a variety of finance, strategy, and general management positions. Mr. Clancy serves as a member of the board of directors of Agios Pharmaceuticals, Inc., Incyte Corporation, Exact Sciences Corporation and Sionna Therapeutics. Mr. Clancy is a senior visiting lecturer of finance at Cornell University’s Graduate School of Business. Mr. Clancy received his B.S. in business administration from Babson College and an MBA from Columbia Business School.